#VisualAbstract: Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Tag: Nivolumab
Nivolumab plus ipilimumab does not improve survival in post-nephrectomy patients with renal cell carcinoma
1. Disease-free survival in the placebo group was 50.7 months and was never reached in the intervention group; however, there ...
#VisualAbstract: Second-line immunosuppression associated with worse outcomes for immune-related adverse events in melanoma
1. Median overall survival was longer in patients receiving steroid-only treatment for adverse events associated with immune response. 2. Patients ...
#VisualAbstract: Nivolumab plus ipilimumab improves recurrence-free survival in patients with resected advanced melanoma
1. 4-year recurrence-free survival was significantly higher with nivolumab plus ipilimumab compared to placebo. 2. Overall survival was significantly higher ...
Nivolumab plus ipilimumab improves recurrence-free survival in patients with resected advanced melanoma
1. 4-year recurrence-free survival was significantly higher with nivolumab plus ipilimumab compared to placebo. 2. Overall survival was significantly higher ...
Stereotactic body radiation does not improve outcomes in patients with advanced Merkel cell carcinoma receiving nivolumab and ipilimumab
1. Objective response rate was not significantly different in patients treated with stereotactic body radiotherapy compared to those without. 2. ...
#VisualAbstract: FOLFOX in combination with nivolumab and trastuzumab improves survival in metastatic ERBB2⁺ esophagogastric adenocarcinoma
Click to read this study in JAMA Oncology.
FOLFOX combined with nivolumab and trastuzumab in ERBB2-positive esophagogastric adenocarcinoma is an emerging therapy option
1. Overall survival rate at 12 months for the FOLFOX arm and ipilimumab arm was 70% and 57%, respectively. 2. ...
Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer
1. Patients with resectable non-small cell lung cancer (NSCLC) receiving neoadjuvant nivolumab in addition to platinum-based chemotherapy demonstrated longer survival ...
#VisualAbstract: Neoadjuvant nivolumab plus chemotherapy increases event-free survival in resectable non-small-cell lung cancer
1. Neoadjuvant nivolumab plus chemotherapy led to a longer event-free survival and higher percentage of patients with a pathological complete ...